Latest Pharma Insights
Pfizer, Roche Looking Beyond Simple Licensing In China Deals
Multinationals showed up with open arms for partnering with Chinese developers at the recent BIOCHINA meeting, but there were signs approaches are changing and firms are now looking beyond straight licensing.
Scrip - March 18, 2026
Multinationals showed up with open arms for partnering with Chinese developers at the recent BIOCHINA meeting, but there were signs approaches are changing and firms are now looking beyond straight licensing.
Scrip - March 18, 2026
Almirall Eyes China Dermatology Assets Beyond Simcere Partnership
Spanish firm's CSO Karl Ziegelbauer shares with Scrip his views on potential alliances with Chinese and other companies and what Almirall can bring to the table.
Scrip - March 18, 2026
Spanish firm's CSO Karl Ziegelbauer shares with Scrip his views on potential alliances with Chinese and other companies and what Almirall can bring to the table.
Scrip - March 18, 2026
US Facility Fee Rates Drop 50% As Later Due Date Set In OMUFA Reauthorization Trims FDA’s Costs
FY 2026 OMUFA facility fees are $19,188 for OTC monograph drug manufacturers and $12,792 for contract manufacturing organizations also making the products. FY 2025 fees were $37,556 and $25,037.
HBW Insight - March 18, 2026
FY 2026 OMUFA facility fees are $19,188 for OTC monograph drug manufacturers and $12,792 for contract manufacturing organizations also making the products. FY 2025 fees were $37,556 and $25,037.
HBW Insight - March 18, 2026
Pfizer, Roche Looking Beyond Simple Licensing In China Deals
Multinationals showed up with open arms for partnering with Chinese developers at the recent BIOCHINA meeting, but there were signs approaches are changing and firms are now looking beyond straight licensing.
Scrip - March 18, 2026
Multinationals showed up with open arms for partnering with Chinese developers at the recent BIOCHINA meeting, but there were signs approaches are changing and firms are now looking beyond straight licensing.
Scrip - March 18, 2026
Almirall Eyes China Dermatology Assets Beyond Simcere Partnership
Spanish firm's CSO Karl Ziegelbauer shares with Scrip his views on potential alliances with Chinese and other companies and what Almirall can bring to the table.
Scrip - March 18, 2026
Spanish firm's CSO Karl Ziegelbauer shares with Scrip his views on potential alliances with Chinese and other companies and what Almirall can bring to the table.
Scrip - March 18, 2026
FDA Report Highlights Persistent Postmarket Burden In Implants, Commodity Quality Issues
A recent FDA report to Congress reflects ongoing safety issues with orthopedic and cardiac implants, as well as commodities such as syringes and PPE.
Medtech Insight - March 17, 2026
A recent FDA report to Congress reflects ongoing safety issues with orthopedic and cardiac implants, as well as commodities such as syringes and PPE.
Medtech Insight - March 17, 2026
EPA Says Biden-era EtO Standards Threaten Medical Device Access And Supply Chain Security
The Trump EPA wants to loosen restrictions the Biden administration placed on facilities that sterilize medical devices with ethylene oxide, arguing the rollbacks are necessary to ensure device accessibility and supply chain security. Opponents to the rollbacks say EtO is a danger to public health.
Medtech Insight - March 17, 2026
The Trump EPA wants to loosen restrictions the Biden administration placed on facilities that sterilize medical devices with ethylene oxide, arguing the rollbacks are necessary to ensure device accessibility and supply chain security. Opponents to the rollbacks say EtO is a danger to public health.
Medtech Insight - March 17, 2026
AI Precision Testing Will Be Standard Of Care Within 5 Years, Says Waiv CEO After $33M Raise
Owkin has spun out its diagnostics division as Waiv, raising $33m to scale AI precision testing in oncology. Waiv CEO Meriem Sefta tells Medtech Insight why the diagnostic infrastructure underpinning precision medicine is already broken – and how Waiv intends to fix it.
Medtech Insight - March 17, 2026
Owkin has spun out its diagnostics division as Waiv, raising $33m to scale AI precision testing in oncology. Waiv CEO Meriem Sefta tells Medtech Insight why the diagnostic infrastructure underpinning precision medicine is already broken – and how Waiv intends to fix it.
Medtech Insight - March 17, 2026
BCI Maker Paradromics Builds Academic Network To Advance Brain-Computer Interface Research
Paradromics has launched a new academic-industry collaboration with leading brain-computer interface researchers at Stanford, Mass General, Pitt, UC Davis and Michigan aiming to translate BCI research into devices to help people with speech impairment, stroke and Parkinson’s.
Medtech Insight - March 17, 2026
Paradromics has launched a new academic-industry collaboration with leading brain-computer interface researchers at Stanford, Mass General, Pitt, UC Davis and Michigan aiming to translate BCI research into devices to help people with speech impairment, stroke and Parkinson’s.
Medtech Insight - March 17, 2026
US Facility Fee Rates Drop 50% As Later Due Date Set In OMUFA Reauthorization Trims FDA’s Costs
FY 2026 OMUFA facility fees are $19,188 for OTC monograph drug manufacturers and $12,792 for contract manufacturing organizations also making the products. FY 2025 fees were $37,556 and $25,037.
HBW Insight - March 18, 2026
FY 2026 OMUFA facility fees are $19,188 for OTC monograph drug manufacturers and $12,792 for contract manufacturing organizations also making the products. FY 2025 fees were $37,556 and $25,037.
HBW Insight - March 18, 2026
Polpharma Targets Supply Chain Resilience With India Office Launch
Polpharma has opened an India office to work more closely with API suppliers, improve oversight and strengthen supply chain resilience, marking an early strategic move under new CEO Sebastian Szymanek.
Generics Bulletin - March 17, 2026
Polpharma has opened an India office to work more closely with API suppliers, improve oversight and strengthen supply chain resilience, marking an early strategic move under new CEO Sebastian Szymanek.
Generics Bulletin - March 17, 2026
The Generics Bulletin Podcast: 2026 Conferences
The final week of February saw the AAM hold its Access! 2026 annual conference in Miami and Medicines for Europe hold its annual regulatory and scientific affairs conference in Amsterdam. Generics Bulletin was there at both events and our reporters discuss the key takeaways in our latest podcast.
Generics Bulletin - March 17, 2026
The final week of February saw the AAM hold its Access! 2026 annual conference in Miami and Medicines for Europe hold its annual regulatory and scientific affairs conference in Amsterdam. Generics Bulletin was there at both events and our reporters discuss the key takeaways in our latest podcast.
Generics Bulletin - March 17, 2026
Cipla Secures 2033 US Pedmark Generic Entry Under Settlement Agreement
Cipla has agreed to delay US launch of its sodium thiosulfate generic until 2033 – albeit six years before patent expiry – resolving multi-patent litigation with Fennec while leaving key commercial terms undisclosed.
Generics Bulletin - March 17, 2026
Cipla has agreed to delay US launch of its sodium thiosulfate generic until 2033 – albeit six years before patent expiry – resolving multi-patent litigation with Fennec while leaving key commercial terms undisclosed.
Generics Bulletin - March 17, 2026
Ascent Fails On US Myrbetriq Challenge As Court Upholds Astellas Mirabegron Patents
Ascent had hoped to join a growing field of US mirabegron competitors, but a Delaware court found its ANDA product would infringe valid Astellas patents covering the sustained-release formulation.
Generics Bulletin - March 17, 2026
Ascent had hoped to join a growing field of US mirabegron competitors, but a Delaware court found its ANDA product would infringe valid Astellas patents covering the sustained-release formulation.
Generics Bulletin - March 17, 2026
Astellas Bets On Degradation Over Inhibition In Race To Crack KRAS G12D
Astellas head of oncology development on why a pan-KRAS degrader and a modality-first strategy could define the big pharma’s next chapter.
In Vivo - March 16, 2026
Astellas head of oncology development on why a pan-KRAS degrader and a modality-first strategy could define the big pharma’s next chapter.
In Vivo - March 16, 2026
The Autonomous Lab: Part 2
In this two-part series, In Vivo examines who is building the autonomous lab, what architectural and business model choices they are making, and what the implications are for drug discovery organizations, external R&D partnerships and the workforce that will be asked to operate these systems.
In Vivo - March 16, 2026
In this two-part series, In Vivo examines who is building the autonomous lab, what architectural and business model choices they are making, and what the implications are for drug discovery organizations, external R&D partnerships and the workforce that will be asked to operate these systems.
In Vivo - March 16, 2026
Deals In Depth: February 2026
Nine $1bn+ alliances were penned in February, and three exceeded $2bn. In the top alliance by deal value, Innovent Biologics entered into a potential $8.85bn collaboration with Eli Lilly to advance novel medicines in oncology and immunology.
In Vivo - March 16, 2026
Nine $1bn+ alliances were penned in February, and three exceeded $2bn. In the top alliance by deal value, Innovent Biologics entered into a potential $8.85bn collaboration with Eli Lilly to advance novel medicines in oncology and immunology.
In Vivo - March 16, 2026